Trial reportAntimicrobial agents and chemotherapy2005
Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.
Trial report in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections.PloS one · 2013Pooled it
- Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Clinical pharmacokinetics · 2017Trial
- Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.Antimicrobial agents and chemotherapy · 2011Trial
- Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.Antimicrobial agents and chemotherapy · 2011Trial
- Bacterial Carbonic Anhydrase Inhibitor CAI0019 Demonstrates Efficacy inACS infectious diseases · 2026Article
- Efficacy and Safety of Contezolid as an Alternative to Linezolid for Treating MRSA Spinal Infections Following Linezolid-Induced Thrombocytopenia: A Single-Center Retrospective Study.Infection and drug resistance · 2026Article
- Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment.Drug design, development and therapy · 2025Article
- Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients.European journal of clinical pharmacology · 2024Article
- Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients.Antimicrobial agents and chemotherapy · 2023Article
- Infant Exposure to Antituberculosis Drugs via Breast Milk and Assessment of Potential Adverse Effects in Breastfed Infants: Critical Review of Data.Pharmaceutics · 2023Review
- Evaluation of 1,3,4-Thiadiazole Carbonic Anhydrase Inhibitors for Gut Decolonization of Vancomycin-Resistant Enterococci.ACS medicinal chemistry letters · 2023Article
- A Review of Population Pharmacokinetic Analyses of Linezolid.Clinical pharmacokinetics · 2022Review
- Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis.Pharmaceutics · 2022Article
- Article
- Article
- Towards a Quantitative Mechanistic Understanding of Localized Pulmonary Tissue Retention-A Combined In Vivo/In Silico Approach Based on Four Model Drugs.Pharmaceutics · 2020Article
- Physicochemical Compatibility and Stability of Linezolid with Parenteral Nutrition.Molecules (Basel, Switzerland) · 2019Article
- Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.International journal of antimicrobial agents · 2018Article
- Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.British journal of clinical pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid is a new antimicrobial agent effective against drug-resistant gram-positive pathogens which are common causes of infections in hospitalized patients. Many such patients rely on the intravenous or enteral route for nutrition and drug administration. Therefore, the bioavailability of linezolid administered enterally in the presence of enteral feedings in hospitalized patients was examined. Eighteen subjects were assessed in a randomized single-dose crossover study; 12 received continuous enteral feedings, while 6 did not (controls). Both groups received linezolid 600 mg intravenously and orally (control) or enterally, with the alternate route of administration separated by a 24-h washout period. Pharmacokinetic parameters derived from noncompartmental and compartmental analysis incorporating linear and nonlinear elimination pathways were compared between groups: F, Ka, Vs, K23, K32, Vmax, Km, and K20 (bioavailability, absorption rate constant, volume of central compartment normalized to body weight, intercompartmental rate constants, maximum velocity, Michaelis-Menten constant, and elimination rate constant, respectively). Pharmacokinetic (PK) data were available from 17 patients. The linezolid oral suspension was rapidly and completely absorbed by either the oral or enteral route of administration. Bioavailability was unaltered in the presence of enteral feedings. PK estimates remain similar regardless of the model applied. At the therapeutic dose used, only slight nonlinearity in elimination was observed. A linezolid oral suspension may be administered via the enteral route to hospitalized patients without compromise in its excellent bioavailability and rapid rate of absorption. Compartmental pharmacokinetic analysis offers a more flexible study application, since bioavailability (F) can be estimated directly with intermixed intravenous/oral doses without a need for a washout period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.